INOVIO Reports Results From REVEAL 1 Phase 3 Trial Evaluating VGX-3100 For Treatment Of High-Grade Precancerous Cervical Dysplasia Caused By HPV-16/HPV-18: Trial Achieved Primary, Secondary Efficacy Endpoints